


Beyond particle size: Introducing the Morphologi 4-ID and MDRS

Dr Robert Taylor Product Technical Specialist – Analytical Imaging Robert.taylor@malvernpanalytical.com



Overview





Introduction to Imaging and MDRS



Introduction to Morphologi 4 and 4-ID



Pharma – Nasal Sprays




Pharma – Polymorphism


Food - Flour


Metallurgy – Additive manufacture

Why characterize particles?












Beyond particle size Why measure particle shape





How can particle shape be measured? Traditional methods







Why Automated Image Analysis ?

- Fast measurement compared with manual microscopy
- Statistically significant sampling: typically 10,000 500,000 particles in one measurement (size range: ~0.5 - 1300um)
 - Measures size and shape (from 2D images)
- SOP driven measurements from dispersion through to results analysis
 - Eliminates operator bias and fatigue
 - Transferability of measurements from site to site



SPEED

Higher throughput Faster measurements ➢ Up to 25% reduction

CONTROL

Intuitive method development Fully-enclosed system






DEFINITION

Enhanced shape differentiation (sharp edge) Increased sensitivity to low contrast samples

RANGE


Extended particle sizing range





Automated Image Analysis


- 2 LED light sources
 - reflected (episcopic)
 - and transmitted (diascopic) illumination
- 18 Mega pixel digital camera
- Motorized objective revolver for automatic magnification changeover
- Precision XY stage for scanning sample & motorized Z axis actuator
- Sample dispersion unit (SDU)
- Integrated spectrometer (4-ID variant only)






Morphological imaging workflow








Morphological results Particle size



- Capture 2D digital image of particle
- Binarise 2D image using foreground segmentation
- Calculate size and shape parameter



Morphological shape descriptors Summary




- Circular equivalent (CE) diameter
- Length
- Width
- Particle form

Aspect ratio =
$$\frac{width}{length}$$

Elongation = $1 - \frac{width}{length}$

- Particle outline
 - Convexity (perimeter)
 - Solidity (area)
- Combination of form and outline
 - Circularity/HS circularity
- Light transmission
 - Intensity mean
 - Intensity SD







Result interpretation

Individual particle detail








How can particle shape be measured?

© 2019 Malvern Panalytical

Dark

Light



Result interpretation


Scattergram

Result interpretation






Group	Record #	Sample Name	Date	Edited	# Particles	CE Diameter Mean (µm)	HS Circularity Mean	Aspect Ratio Mean	Elongation Mean	Solidity Mean	Convexity Mean
	19	A	20 September 2006 11:30:33	True	5701	204.56	0.667	0.777	0.223	0.913	0.901
	20	В	20 September 2006 12:58:58	True	5963	188.44	0.639	0.775	0.225	0.899	0.891
	21	С	20 September 2006 15:55:37	True	4535	201.47	0.624	0.786	0.214	0.895	0.881
	22	D	20 September 2006 17:22:35	True	4091	219.06	0.603	0.776	0.224	0.884	0.877
	23	Ε	20 September 2006 18:33:52	True	7013	183.93	0.640	0.784	0.216	0.903	0.888
	24	F	21 September 2006 10:03:19	True	4220	208.10	0.585	0.750	0.250	0.878	0.876



MDRS workflow

Morphologically-Directed Raman Spectroscopy






MDRS workflow

Morphologically-Directed Raman Spectroscopy







Morphologically-Directed Raman Spectroscopy



Combines automated imaging and Raman spectroscopy in one integrated platform



Chemical identity




Using libraries


1. Export particle spectrum from Morphologi to KnowltAll



2. KnowItAll identifies the particle




3. Add Spectrum to internal library





4. Compare other particle spectra to internal library




© 2019 Malvern Panalytical

Chemical analysis Results

- Create component specific classifications
- Compare size distributions of components within a mixture
- CE Diam. (vol) for Mixture, API(32.15%) and Excipient (67.85%)

Sample Name:			
Nasal Spray FP	D[v,0.1] µm: 3.5	D[v,0.5]µm: 6.3	D[v,0.9]µm: 11.9
API	D[v,0.1] µm: 4.1	D[v,0.5]µm: 6.9	D[v,0.9]µm: 8.9
Excipient	D[v,0.1] µm: 3.4	D[v,0.5]µm: 5.9	D[v,0.9]µm: 13.3

Volume transformation: CEDiameter (μm) smoothed over 66 points








Orally Inhaled and Nasal Drug Products (OINDPs)



Inhaled (locally-acting) generic formulation Benefit of Q3 equivalence testing





Generics bioequivalence requirements



	Requirement	Definition
Q1	Qualitatively the same	Test and RLD products contain the same active (API) and inactive (excipient) ingredients.
Q2	Quantitatively the same	Test and reference products contain the same concentration of API and excipient ingredients.
Q3	Physicochemical attributes are the same	Test and reference products have the same arrangement of matter (microstructure)

Q3 physicochemical properties may include:

- Globule Size Distribution
- Particle Size Distribution
- Rheological behaviour
- Particle charge


- Polymorphic Form
- Phase Behaviour
- Morphology
- Molecular structure

Robert Lionberger, Office of Generic Drugs, CDER, FDA. Pharmaceutical Science of Generic Drugs: The Science of Equivalence. NIPTE Research Conference, April 30, 2015.


Case study 1: Nasal spray Morphological analysis



Sharp Edge can help to improve the image quality of the particles




Generic Nasal Spray



RLD


Case Study 1: bioequivalence of Nasal sprays





Case study 1: bioequivalence of Nasal sprays







© 2019 Malvern Panalytical

28

Case study 1: Nasal spray MDRS comparison of the shape of the API and excipient







Case study 1: bioequivalence of Nasal sprays FDA recognises the use of MDRS in establishing in vitro bioequivalence

"Apotex used data from an *in vitro* approach utilizing innovative technology... called Morphologically-Directed Raman Spectroscopy (MDRS)."

"Successful use of this technology sets a precedent to accept an *in vitro* approach in lieu of a clinical endpoint BE study." al tro FDA/CDER SBIA CHRONICLES FDA Embraces Emerging Technology for Bioequivalence Evaluation of Locally Acting Nasal Sprays

> Dr. Bing Li Acting Director Office of Generic Drugs

"FDA is very happy to have approved an application that included this innovative technology just four years after it became available. This shows our inclination to embrace emerging technology..."

https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/SmallBusinessAssistance/UC M502012.pdf

© 2019 Malvern Panalytica

30

Nasal sprays Recent Guidance from Oct 2016




Draft Guidance on Triamcinolone Acetonide

This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs.

Active Ingredient:	Triamcinolone acetonide	
Dosage Form; Route:	Metered spray; nasal	
Prescribing Information:	Over-the-counter (OTC)	
Recommended Studies:	In vitro and in vivo studies	
The Agency recommends the following in vitro and in vivo studies to establish bioaquivale		

The Agency recommends the following in vitro and in vivo studies to establish bioequivalence (BE) of the test (T) and reference (R) nasal sprays containing triamcinolone acetonide.

-Alternate approach to the comparative clinical endpoint study:
- A clinical endpoint BE study is recommended ... because of an inability to adequately characterize drug particle size distribution (PSD)using commonly used analytical methods. If drug PSD in the T and R products can be accurately measured using a validated analytical method such as morphologically directed Raman spectroscopy or any other advanced methodology, sponsors may submit comparative particle size distribution data as part of their drug characterization within their ANDA application.



Process induced attrition





Process induced attrition

Some powders are more prone to attrition than others and this can affect quality

- Surface abrasion, chipping
- Generate fines
 - Bimodal dissolution profile
 - Fast then slow
 - Alter the intended release profile
 - Increase adhesion to tooling
 - Create particles with satellites
 - Change flow characteristics
 - Product out of specification
- Fragmentation
- Significant reduction in size
 - Alter the PSD of the API
 - Product out of specification








John Gamble et. al. International Journal of Pharmaceutics 470 (2014) 77-87

© 2019 Malvern Panalytical 29 May 2019

Pharmaceutical formulation processing





---- = initial API; ---- = API in lactose formulation; + + + = API in lactose and MCC formulation; --- + --- = API in MCC formulation.


conclusions



- Similar low level attrition seen with tumble blended and cone milled processes
- More pronounced, high level attrition from the roller compaction process
- Both excipients caused more attrition than API alone
- MCC caused higher level of attrition than lactose

If particle size and shape is **critical to quality** then the formulation, blending and milling processes should be optimised to **control process induced attrition**

Use MDRS to test the effect of processes



polymorphism



Polymorphism

"A polymorph is a solid crystalline phase of a given compound resulting from the possibility of at least two different arrangements of the molecules of that compound in the solid state." – McCrone, 1965



- Drug performance bioavailability and manufacturing
- Solubility: different polymorphs can have significantly different aqueous solubility.
- Crystal habit: differing density and shape may influence the flowability and packing density of the powder, but also the rate of dissolution.
- Stability: less stable polymorph can **convert** to more stable polymorph.
- Batch composition: all batches have the same polymorphs to the same ratio GLP.
- Intellectual Property
- Fully characterised: all polymorphs identified and protected.

CASE STUDY 1: POLYMORPHS B AND C



Particle class - Polymorph B




Particle class - Polymorph C



Case study 1: Composition by number of particles





Case study 2: Acetaminophen




- Type 1 and Type 2 polymorphs
- A sample containing a mixture of type 1 and type 2 was created by
 - Recrystallizing a saturated solution of type 1 by cooling slowly
 - Recovered material dried at 75C
 - Half of the sample removed and heated to 170C to convert to Type 2
 - A mixture of 9 parts Type 1 and Type 2 milled in a hand mill

Case study 2: Morphological results




- 70,000 particles measured by automated image analysis
- 1375 particles targeted for chemical analysis
- Use the morphological result to classify particles for chemical analysis
 - >50µm
 - 25µm to 50µm
 - 10µm to 25µm



Case study 2: Chemical results

- Particles identified by correlation to library spectra
- Spectral range masking applied
 - 1200cm-1 to 1260cm-1
 - 1540cm-1 to 1590cm-1
- 1220 particles identified as Type 1
- 144 particles identified as Type 2
 - 10.5% of the total
- 11 particles show features from both type 1 and type 2
 - Aggregates formed during milling or dispersion






Case study 2: Linking ID to morphology



- Biggest difference is in the Intensity Mean
 - Type 1 particles are more transparent
 - However, there is an overlap so chemical identification is still required



conclusions



- Characterise the polymorph composition using MDRS
- Perform morphological analysis on each polymorph
 - Correlate to powder performance
 - Flowability
 - Packing density
 - Dissolution rate



Context for flours

- Three different flour products
 - · Leading brand wheat flour
 - Supermarket brand wheat flour
 - Gluten free flour
- Composition of flour
 - Starch
 - Wheat
 - Rice, potato, maize, tapioca, buckwheat (gluten free)
 - Protein
 - Trace constituents
- Starch has two particle types:
 - A-type: >10 μm
 - B-type: <10 µm





- A-type particle function
 - Higher gelatinization enthalpy
 - · Higher peak viscosity of paste
 - Higher final viscosity of paste
- B-type particle function
 - Higher farinograph water absorption
 - Higher glycemic index

Particle size distribution by volume Mastersizer 3000



- Comparable distributions for leading brand and supermarket brand of wheat flour
- Gluten free flour very different
- What causes this difference?





Particle size distribution by number

Raman spectral library



Starch-protein composite

A particle spectrum and the library spectra


Correlate particle spectrum to library spectra

Correlations	
	Particle ID 9417
Starch	0.994
Calcium sulphate	0.105
Calcium carbonate	0.172
Gamma-oryzanol	0.088
Protein	0.593
Starch-protein c	0.959

This particle had the highest correlation to Starch

Composition % number






Particle size distribution of starch


Number distribution





- Lead brand - Supermarket brand - Gluten free

Circularity of A and B-type starch



© 2019 Malvern Panalytical


III.

Malvern Panalytical

a spectris company

Elongation distribution of starch





- Lead brand - Supermarket brand - Gluten free

Conclusions

Flours

Three flour brands compared by MDRS



- Starch was the main component with a substantial amount of protein for the standard wheat flours (Lead and supermarket brands).
- Most protein agglomerated with starch to form composite particles
- Notably less protein in gluten free brand
- The starch in the standard wheat flour brands had a bimodal size distribution from the A and B-type particles, whereas the gluten free product was monomodal.
 - B-type particles more spherical than A-type particles
 - Gluten free product was biased towards A-type particles
- Gluten free particles were more spherical than the standard flours
- This will likely affect the manufacturing processes of the flour and structural and nutritional performance of the dough.

© 2019 Malvern Panalytical

55



Metallurgy Additive Manufacture



May 29, 2019


Applications: Powder metallurgy Common processes



- Additive Manufacturing: AM
 - Laser Beam Melting: LBM
 - Electron Beam Melting: EBM
 - Direct Energy Deposition: DED/ Laser Metal Deposition: LMD
 - 3D printing
- Metal Injection Moulding: MIM
- Hot Isostatic Pressing: HIP
- Cold Isostatic Pressing: CIP
- Press and Sinter

Applications: Additive manufacturing Processes (Laser Beam/Electron Beam Melting)






Why is particle morphology important? Powder bed formation

Powder Bed

Formation




- Good powder flowability
 - Cohesive fine particles affect flowability
 - Irregular particles increase interlocking and reduce flowability
 - · Irregular and satellited particles can be quantified in classifications



Why is particle morphology important? Powder bed formation






James P. Bennett & Jeffery D. Smith, Ceramic Transactions, Volume 25, 2001 (American Chemical Society)


Why is particle morphology important? Powder bed formation





Why is particle morphology important? Processes (Laser Beam/Electron Beam Melting)






[1] Y.S. Lee and W. Zhang, Mesoscopic simulation of heat transfer and fluid flow in laser powder bed additive manufacturing, 2015, <u>http://sffsymposium.engr.utexas.edu/</u>

Why is particle morphology important? Recycling









- In LBM/EBM additive manufacture, the integrity of the part is dependent on the quality of the powder bed
 - · A homogeneous, high density powder bed is required to form a continuous, defect free layer
- The right balance of coarse and fine particles are required to maximise packing density
- Particle shape will also affect flowability and packing density
- Characterise both particle size and shape of the virgin powder using Automated Image Analysis
- Characterise both particle size and shape of the recycled powder using Automated Image Analysis

Summary





Introduction to Imaging and MDRS



Pharma – Polymorphism

Food - Flour

Metallurgy – Additive manufacture

© 2019 Malvern Panalytical





4-ID

Introduction to Morphologi 4 and

Pharma – Nasal Sprays

Thank you for your attention

www.malvernpanalytical.com